Georg Maiwald

Georg Maiwald is a notable inventor based in Vienna, Austria. He has made significant contributions to the field of biotechnology, particularly in the development of peptides that target various strains of HIV-1. With a total of 3 patents to his name, Maiwald's work is at the forefront of medical innovation.

Latest Patents

One of Maiwald's latest patents involves peptides that induce antibodies which neutralize genetically divergent strains of HIV-1. This invention focuses on peptides that bind to antibodies exhibiting neutralizing activity against different strains and clinical isolates of HIV-1. These peptides are designed to inhibit the fusion of cells infected with HIV-1 and can be combined with an adjuvant, presented as recombinant fusion proteins, chemically coupled to carrier molecules, or as recombinant antibodies. Another significant patent relates to fusion peptides wherein at least one peptide consists of an amino acid sequence selected from a specific group. This peptide is bound to an adjuvant, which is a protein molecule, through the fusion of nucleotide sequences and subsequent expression in a biological system.

Career Highlights

Throughout his career, Georg Maiwald has focused on innovative solutions in the field of peptide technology. His work has the potential to impact the treatment of HIV-1, showcasing his commitment to advancing medical science.

Collaborations

Maiwald has collaborated with esteemed colleagues such as Hermann W Katinger and Florian Ruker. These partnerships have further enhanced his research and development efforts in the biotechnology sector.

Conclusion

Georg Maiwald is a prominent inventor whose work in peptide technology is paving the way for new treatments against HIV-1. His innovative patents and collaborations highlight his dedication to improving healthcare through scientific advancements.